

Investigational Pipeline

The agents below are not approved for the uses listed by any regulatory agency as efficacy and safety have not been established.

Efgartigimod

Target:
FcRn

Ongoing
Clinical Trials

Preclinical

Phase 1

Proof of Concept

Registrational



Seronegative Generalized Myasthenia Gravis (IV) (SC)*



Ocular Myasthenia Gravis (oMG) (SC)



Primary Immune Thrombocytopenia (ITP) (IV)



Graves' Disease (SC)



Myositis (IMNM, ASyS, DM) (SC)



Sjogren's Disease (SC)



Systemic Sclerosis (SC)



Antibody-Mediated Rejection (AMR) (SC)



Empasiprubart

Target:
C2



Multifocal Motor Neuropathy (MMN)



Delayed Graft Function (DGF)



Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)



Adimanebart

Target:
MuSK



Congenital Myasthenic Syndrome (CMS)



Spinal Muscular Atrophy (SMA)



Neurology Rheumatology Nephrology Endocrinology Hematology

*SC is being investigated in ADAPT-SC and ADAPT-SC+.

Abbreviations: ASyS, antisynthetase syndrome; C2, complement factor 2; DM, dermatomyositis; FcRn, neonatal Fc receptor; IMNM, immune-mediated necrotizing myopathy; IV, intravenous; MuSK, muscle-specific tyrosine kinase; SC, subcutaneous.

argenx

©2026 argenx MED-US-a117-2400012 v9.0
March 2026